DE60237087D1 - Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid - Google Patents

Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid

Info

Publication number
DE60237087D1
DE60237087D1 DE60237087T DE60237087T DE60237087D1 DE 60237087 D1 DE60237087 D1 DE 60237087D1 DE 60237087 T DE60237087 T DE 60237087T DE 60237087 T DE60237087 T DE 60237087T DE 60237087 D1 DE60237087 D1 DE 60237087D1
Authority
DE
Germany
Prior art keywords
nsaid
pharmaceutical compositions
dosage form
release
coordinated delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237087T
Other languages
English (en)
Inventor
John R Plachetka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pozen Inc
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23134063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60237087(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pozen Inc filed Critical Pozen Inc
Application granted granted Critical
Publication of DE60237087D1 publication Critical patent/DE60237087D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60237087T 2001-06-01 2002-05-31 Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid Expired - Lifetime DE60237087D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29458801P 2001-06-01 2001-06-01
PCT/US2002/017105 WO2002098352A2 (en) 2001-06-01 2002-05-31 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs

Publications (1)

Publication Number Publication Date
DE60237087D1 true DE60237087D1 (de) 2010-09-02

Family

ID=23134063

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237087T Expired - Lifetime DE60237087D1 (de) 2001-06-01 2002-05-31 Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid

Country Status (18)

Country Link
US (1) US6926907B2 (de)
EP (3) EP2260837A1 (de)
JP (1) JP4756823B2 (de)
AT (1) ATE474559T1 (de)
AU (3) AU2002305758B2 (de)
BE (1) BE2011C016I2 (de)
CA (1) CA2449098C (de)
CY (1) CY1110842T1 (de)
DE (1) DE60237087D1 (de)
DK (1) DK1411900T4 (de)
EA (1) EA006398B1 (de)
ES (1) ES2348710T5 (de)
IL (2) IL159129A0 (de)
LU (1) LU91858I2 (de)
MX (1) MXPA03011017A (de)
NO (2) NO333836B1 (de)
PT (1) PT1411900E (de)
WO (1) WO2002098352A2 (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6902746B2 (en) * 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
DK1617832T3 (da) 2003-04-29 2008-07-07 Orexigen Therapeutics Inc Præparater til påvirkning af vægttab
EP1673073A4 (de) * 2003-09-29 2012-03-21 Cj Cheiljedang Corp Formulierungen mit verzögerter freisetzung
KR100762846B1 (ko) * 2003-09-29 2007-10-04 씨제이 주식회사 서방성 제제
WO2005074930A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
EP1750767A4 (de) * 2004-05-25 2010-09-22 Santarus Inc Pharmazeutische formulierungen zur hemmung der säuresekretion und herstellungs- und anwendungsverfahren
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
US20080096927A1 (en) * 2004-08-24 2008-04-24 Simon Thomas J Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
DE602005009016D1 (de) * 2004-12-06 2008-09-25 Janssen Pharmaceutica Nv Orale suspension mit meloxicam
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
CA2511158A1 (en) * 2005-06-29 2006-12-29 Medical Futures Inc. Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against nsaid gastropathy
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
NZ565846A (en) * 2005-07-18 2011-12-22 Horizon Therapeutics Inc Medicaments containing famotidine and ibuprofen and administration of same
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
EP1965774A2 (de) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Orale pharmazeutische formulierungen mit nichtsteroidalen entzündungshemmern und säurehemmern
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
ES2699444T3 (es) 2006-04-04 2019-02-11 Kg Acquisition Llc Formas de dosificación oral que incluyen un agente antiplaquetario y un inhibidor ácido
WO2007129178A2 (en) 2006-04-28 2007-11-15 Wockhardt Ltd Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor
CH696229A5 (fr) * 2006-05-13 2007-02-28 Professeur Dr Achille Benakis Nouvelles formes galéniques de l'Artemisinine et ses dérivés en association avec d'autres antipaludéens pour le traitement de la malaria.
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
ATE539747T1 (de) * 2006-07-18 2012-01-15 Horizon Therapeutics Inc Verfahren und medikamente zur verabreichung von ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20150224056A1 (en) * 2006-07-18 2015-08-13 Horizon Pharma Usa, Inc. Pharmaceutical compositions of ibuprofen and famotidine
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
US20100305074A1 (en) * 2007-04-04 2010-12-02 Hight H Thomas Niacin-based pharmaceutical compositions
US20100221334A1 (en) * 2007-07-19 2010-09-02 Fink Mitchell P Compositions including leukotriene antagonists and nsaids and methods of using the same
NZ587202A (en) * 2008-01-04 2013-03-28 Schabar Res Associates Llc Methods for measuring a patient response upon administration of a drug and compositions thereof
US20090186086A1 (en) * 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
JP2012502015A (ja) * 2008-09-09 2012-01-26 アストラゼネカ・アクチエボラーグ 必要がある患者に医薬組成物を送達するための方法
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
US8246988B2 (en) * 2009-01-05 2012-08-21 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
CA2748728C (en) * 2009-01-05 2017-01-03 Mcneil-Ppc, Inc. Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
US8252330B2 (en) * 2009-01-05 2012-08-28 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
EA201290026A1 (ru) * 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
WO2010151697A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
CN102711835B (zh) * 2009-11-27 2014-12-10 努沃研究股份有限公司 局部布洛芬制剂
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
EP2600877A4 (de) 2010-08-04 2014-05-07 Borody Thomas J Zusammensetzungen zur darmflora-transplantation und verfahren zu ihrer herstellung und verwendung sowie verfahren zu ihrer verabreichung
SG190717A1 (en) 2010-12-03 2013-07-31 Takeda Pharmaceutical Orally disintegrating tablet
CA2821196C (en) 2010-12-13 2022-11-22 Thomas Julius Borody Gastric and colonic formulations and methods for making and using them
EP2683390B1 (de) 2011-03-09 2017-05-03 Regents Of The University Of Minnesota Zusammensetzungen und verfahren zur transplantation von biozönose des kolon
WO2012173581A1 (en) 2011-03-21 2012-12-20 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Thiocolchicoside, etodolac and famotidine combinations
TR201103752A2 (tr) 2011-04-18 2012-11-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Tiyokolşikozit, diklofenak ve lansoprazol kombinasyonları.
WO2012170676A1 (en) 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
WO2013054352A1 (en) 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
CN102247369B (zh) * 2011-08-18 2012-11-21 天津市嵩锐医药科技有限公司 复方萘普生埃索美拉唑药物组合物及其制备方法
CN102247371A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布洛芬和拉呋替丁为活性成分的药物组合物
EP2755641A4 (de) 2011-09-14 2015-03-18 Pozen Inc Kontrollierte dosierung von clopidogrel bei magensäurehemmungstherapien
MY186477A (en) 2011-11-30 2021-07-22 Takeda Pharmaceuticals Co Dry coated tablet
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN104540521A (zh) 2012-06-04 2015-04-22 高拉夫·阿格拉沃尔 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
WO2014007778A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi COMBINED IMMEDIATE RELEASE FORMULATIONS OF NSAIDs
WO2014007777A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combined capsule formulations of nsaids
JP6454640B2 (ja) 2012-07-27 2019-01-16 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． 結腸排出促進における使用のための製剤および製剤製造方法
US20160089363A1 (en) 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
MX2021011641A (es) 2013-12-24 2023-03-10 Durect Corp Usos de sulfatos de colesterol oxigenados (soc).
WO2015150943A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited Pharmaceutical composition of nsaid and ppi or salt thereof
KR101723266B1 (ko) 2014-08-13 2017-04-05 영남대학교 산학협력단 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 경구용 속방형 조성물 및 그 제조방법
WO2016106315A1 (en) * 2014-12-23 2016-06-30 Fmc Corporation Enteric film coating compositions, method of coating, and coated forms
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
MX2017014488A (es) 2015-05-14 2018-06-11 Crestovo Holdings Llc Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos.
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
SG11201800591TA (en) 2015-07-30 2018-02-27 Takeda Pharmaceuticals Co Tablet
EP3352773A4 (de) 2015-09-24 2019-03-27 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation Antibakterielle und schützende bakteriophagenformulierungen sowie verfahren zur herstellung und verwendung davon
RS63260B1 (sr) * 2015-11-25 2022-06-30 Axsome Therapeutics Inc Farmaceutske kompozicije koje obuhvataju meloksikam
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2018004498A1 (en) 2016-06-30 2018-01-04 Imuneks Farma Ilac San. Ve Tic. A.S. Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
TR201717134A2 (tr) 2016-12-07 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı Ve Enflamasyonun Hızlı Tedavisi İçin Diklofenak Ve H2 Reseptör Antagonistlerinin Çabuk Salımlı Oral Kombinasyonları
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
PT3565550T (pt) 2017-01-04 2021-01-20 Axsome Therapeutics Inc Composições farmacêuticas compreendendo meloxicam e rizatriptano
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
CA3064773A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
TR201718099A2 (tr) 2017-11-16 2019-06-21 Mehmet Nevzat Pisak Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar
WO2019135725A1 (en) 2018-01-03 2019-07-11 Pisak Mehmet Nevzat Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation
WO2020013781A2 (en) * 2018-03-27 2020-01-16 Pisak Mehmet Nevzat Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation
WO2020018048A2 (en) * 2018-05-28 2020-01-23 Pisak Mehmet Nevzat An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) * 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US20220125732A1 (en) * 2020-10-23 2022-04-28 Appco Pharma Llc Ibuprofen and famotidine tablet
WO2023079094A1 (en) 2021-11-05 2023-05-11 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2105193B (en) 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4554276A (en) * 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4522826A (en) 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4766117A (en) * 1984-10-11 1988-08-23 Pfizer Inc. Antiinflammatory compositions and methods
US4704278A (en) * 1984-10-17 1987-11-03 American Home Products Corp (Del) Fluidized magaldrate suspension
US4676984A (en) * 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5037815A (en) * 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US4965065A (en) * 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US5043358A (en) * 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5260333A (en) * 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
EP0320550A1 (de) 1987-12-18 1989-06-21 Bristol-Myers Company NSAID-Zusammensetzungen mit Gehalt an H1-Blockern, H2-Blockern, beta-adrenergischen Agonisten oder Mischungen hiervon und an einem Alkalinisierungsmittel
NZ235877A (en) 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
EP0574424A1 (de) * 1991-03-04 1993-12-22 Warner-Lambert Company Salz/ionpaare von nicht-steroiden enzündungshemmenden arzneimitteln in verschiedenen dosierungsformen
DK0550083T3 (da) 1991-12-06 1999-10-11 Glaxo Group Ltd Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra
WO1993012817A1 (en) 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1994007541A1 (en) 1992-09-29 1994-04-14 Merck & Co., Inc. Ibuprofen-h2 antagonist combinations
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
AU7961094A (en) * 1993-10-19 1995-05-08 Procter & Gamble Company, The Picosulphate dosage form
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US5547608A (en) * 1994-09-09 1996-08-20 Basf Corporation Polyurethane SRIM compositions having internal mold release properties
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
EP1017370B1 (de) 1997-09-11 2003-10-29 Nycomed Danmark ApS Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
AU747099B2 (en) * 1997-10-31 2002-05-09 Pharmacia Corporation Gellan gum tablet coating
ATE303809T1 (de) * 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
DE19801811B4 (de) 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
CA2320963A1 (en) 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
AU2481899A (en) * 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
GB9814215D0 (en) * 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
WO2000018377A1 (en) * 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
US6485747B1 (en) * 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
AU4198899A (en) 1999-05-20 2000-12-12 Par Pharmaceutical, Inc. Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
CA2277407A1 (en) * 1999-07-14 2001-01-14 Bernard Charles Sherman Pharmaceutical tablet comprising an nsaid and misoprostol
US6126816A (en) * 1999-07-14 2000-10-03 Ruiz, Jr.; Reuben F. Wastewater treatment device
US6787164B2 (en) * 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020045184A1 (en) 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida

Also Published As

Publication number Publication date
CA2449098C (en) 2010-01-05
BE2011C016I2 (de) 2021-07-19
US20030069255A1 (en) 2003-04-10
LU91858I2 (fr) 2011-10-24
MXPA03011017A (es) 2005-04-29
DK1411900T3 (da) 2010-10-25
AU2002305758B2 (en) 2006-09-07
PT1411900E (pt) 2010-10-11
EP2163241A1 (de) 2010-03-17
EP1411900A4 (de) 2007-06-27
NO2013014I2 (no) 2013-10-17
WO2002098352A3 (en) 2003-06-26
EP1411900A2 (de) 2004-04-28
EA200301321A1 (ru) 2004-06-24
AU2009200966A1 (en) 2009-04-02
EA006398B1 (ru) 2005-12-29
IL159129A (en) 2014-07-31
EP1411900B2 (de) 2013-12-04
AU2002305758C1 (en) 2002-12-16
AU2006235929B2 (en) 2008-12-11
CY1110842T1 (el) 2015-06-10
NO20035275D0 (no) 2003-11-27
AU2009200966B2 (en) 2010-06-10
ES2348710T5 (es) 2014-02-17
CA2449098A1 (en) 2002-12-12
JP4756823B2 (ja) 2011-08-24
WO2002098352A2 (en) 2002-12-12
JP2004536809A (ja) 2004-12-09
US6926907B2 (en) 2005-08-09
AU2006235929A1 (en) 2006-11-30
IL159129A0 (en) 2004-05-12
NO333836B1 (no) 2013-09-30
EP2260837A1 (de) 2010-12-15
DK1411900T4 (da) 2014-01-27
NO2013014I1 (no) 2013-10-17
ES2348710T3 (es) 2010-12-13
EP1411900B1 (de) 2010-07-21
ATE474559T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
DE60237087D1 (de) Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
BR9506028A (pt) Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiíferos e no homem e embalagem de ampola de pressão transversal
SE9804314D0 (sv) New pharmaceutical formulation
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
DE69920689D1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
ZA200408649B (en) Opthamological use of roflumilast for the treatment of diseases of the eye
ATE129404T1 (de) Dosierungsform fuer die freisetzung eines witkstoffs in einem kurzen zeitraum.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
BR0008403A (pt) Formulação farmacêutica para administração oral
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
CR7049A (es) Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
HUP0301128A2 (hu) 5-Metil-2-(2'-kloro-6'-fluoranilino)-fenilecetsavat tartalmazó gyógyszerkészítmények ciklooxigenáz-2-vel kapcsolatos betegségek kezelésére és alkalmazásuk
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
BR0318201A (pt) regime de dosagem de fármaco antiinflamatório não-esteroidal
PT1583525E (pt) Utilização de uma combinação de substâncias da síntese de porfirina, salicilatos e anti-oxidantes na fototerapia de doenças da pele e/ou das articulações
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais
UA32862A (uk) Спосіб лікування захворювань шлунково-кишкового тракту
RU2003107504A (ru) Лекарственное средство для лечения хронического обструктивного бронхита
TH65639A (th) องค์ประกอบทางเภสัชกรรม